CCL7 Signaling in the Tumor Microenvironment.

[1]  C. Ferreira,et al.  Cancer immunotherapy: the art of targeting the tumor immune microenvironment , 2019, Cancer Chemotherapy and Pharmacology.

[2]  M. Andersen.  The targeting of tumor-associated macrophages by vaccination , 2019, Cell stress.

[3]  R. Bonecchi,et al.  Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy , 2019, Front. Immunol..

[4]  Jianru Xiao,et al.  High CCL7 expression is associated with migration, invasion and bone metastasis of non-small cell lung cancer cells. , 2019, American journal of translational research.

[5]  J. Pollard,et al.  Targeting macrophages: therapeutic approaches in cancer , 2018, Nature Reviews Drug Discovery.

[6]  Xiangyang Xiong,et al.  Crucial biological functions of CCL7 in cancer , 2018, PeerJ.

[7]  Giuseppe Curigliano,et al.  Targeting the microenvironment in solid tumors. , 2018, Cancer treatment reviews.

[8]  Mogamulizumab Tops Standard of Care for CTCL. , 2018, Cancer discovery.

[9]  M. Duvic,et al.  Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma , 2017, Expert review of hematology.

[10]  G. Fan,et al.  The primary growth of laryngeal squamous cell carcinoma cells in vitro is effectively supported by paired cancer-associated fibroblasts alone , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[11]  D. Webb,et al.  Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. , 2017, Biochemical Society Transactions.

[12]  D. Tuma,et al.  Enhanced colorectal cancer metastases in the alcohol-injured liver , 2017, Clinical & Experimental Metastasis.

[13]  A. Wells,et al.  Distinct Osteomimetic Response of Androgen‐Dependent and Independent Human Prostate Cancer Cells to Mechanical Action of Fluid Flow: Prometastatic Implications , 2017, The Prostate.

[14]  Xin-hua Liang,et al.  The role of tumor microenvironment in collective tumor cell invasion. , 2017, Future oncology.

[15]  Chang Xian Li,et al.  CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation. , 2016, Journal of hepatology.

[16]  Jin Ding,et al.  Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-β pathways. , 2016, Cancer letters.

[17]  F. Thaiss,et al.  CXCR3+ Regulatory T Cells Control TH1 Responses in Crescentic GN. , 2016, Journal of the American Society of Nephrology : JASN.

[18]  W. Lee,et al.  Crosstalk between CCL7 and CCR3 promotes metastasis of colon cancer cells via ERK-JNK signaling pathways , 2016, Oncotarget.

[19]  Yizheng Wang,et al.  Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities , 2016, Oncogene.

[20]  Kathryn J Fowler,et al.  Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. , 2016, The Lancet. Oncology.

[21]  M. Koch,et al.  Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. , 2016, Cancer cell.

[22]  M. Reni,et al.  Basophil Recruitment into Tumor-Draining Lymph Nodes Correlates with Th2 Inflammation and Reduced Survival in Pancreatic Cancer Patients. , 2016, Cancer research.

[23]  M. Golzio,et al.  Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity , 2016, Nature Communications.

[24]  Jing-quan Li,et al.  Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma , 2015, Gut.

[25]  Jeremy J. W. Chen,et al.  Opposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression , 2015, Scientific Reports.

[26]  L. Marti,et al.  Chemokines and immunity , 2015, Einstein.

[27]  O. Elemento,et al.  Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC , 2015, PloS one.

[28]  Y. Sakamoto,et al.  Cancer-associated fibroblast-derived CXCL12 causes tumor progression in adenocarcinoma of the esophagogastric junction , 2015, Medical Oncology.

[29]  Y. Mo,et al.  Roles of the Cyclooxygenase 2 Matrix Metalloproteinase 1 Pathway in Brain Metastasis of Breast Cancer* , 2015, The Journal of Biological Chemistry.

[30]  Doo Young Lee,et al.  Reciprocal Interaction between Carcinoma-Associated Fibroblasts and Squamous Carcinoma Cells through Interleukin-1α Induces Cancer Progression12 , 2014, Neoplasia.

[31]  N. Jamieson,et al.  IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival , 2014, Oncotarget.

[32]  Wei Zhao,et al.  Let-7d suppresses growth, metastasis, and tumor macrophage infiltration in renal cell carcinoma by targeting COL3A1 and CCL7 , 2014, Molecular Cancer.

[33]  Wen Di,et al.  A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients , 2014, Journal of Ovarian Research.

[34]  H. Moch,et al.  Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression , 2013, British Journal of Cancer.

[35]  C. Dray,et al.  Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. , 2013, Cancer research.

[36]  M. Egeblad,et al.  System-Wide Analysis Reveals a Complex Network of Tumor-Fibroblast Interactions Involved in Tumorigenicity , 2013, PLoS genetics.

[37]  E. Bergstralh,et al.  Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case–control studies , 2013, Prostate Cancer and Prostatic Disease.

[38]  S. Freedland,et al.  Obesity and prostate cancer: weighing the evidence. , 2013, European urology.

[39]  T. Wang,et al.  Obesity accelerates Helicobacter felis-induced gastric carcinogenesis by enhancing immature myeloid cell trafficking and TH17 response , 2013, Gut.

[40]  J. Slingerland,et al.  Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. , 2013, Annual review of medicine.

[41]  Xin Zhang,et al.  CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. , 2012, Cell stem cell.

[42]  Y. Cho,et al.  CC chemokine ligand 7 expression in liver metastasis of colorectal cancer. , 2012, Oncology reports.

[43]  J. Rommelaere,et al.  Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment , 2012, Cancer Immunology, Immunotherapy.

[44]  Li‐yu Lee,et al.  CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis. , 2012, World journal of gastroenterology.

[45]  T. Sparwasser,et al.  Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer , 2012, Oncoimmunology.

[46]  Alicia González-Martín,et al.  CCR5 in cancer immunotherapy: More than an “attractive” receptor for T cells , 2012, Oncoimmunology.

[47]  F. Stossi,et al.  Macrophage-Elicited Loss of Estrogen Receptor Alpha in Breast Cancer Cells via Involvement of MAPK and c-Jun at the ESR1 Genomic Locus , 2011, Oncogene.

[48]  G. Dranoff,et al.  CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. , 2011, Cancer research.

[49]  R. Kappelhoff,et al.  Microarray and Proteomic Analysis of Breast Cancer Cell and Osteoblast Co-cultures , 2011, The Journal of Biological Chemistry.

[50]  Lin Zhang,et al.  Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells , 2011, Nature.

[51]  U. Panzer,et al.  CXCR3 Deficiency Exacerbates Liver Disease and Abrogates Tolerance in a Mouse Model of Immune-Mediated Hepatitis , 2011, The Journal of Immunology.

[52]  R. Claus,et al.  CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. , 2010, Cancer research.

[53]  Robert A. Weinberg,et al.  Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts , 2010, Proceedings of the National Academy of Sciences.

[54]  Darren R. Williams,et al.  Tumor‐stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7 , 2010, International journal of cancer.

[55]  M. Aoki,et al.  Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model , 2010, Proceedings of the National Academy of Sciences.

[56]  C. Dive,et al.  Biological mechanisms linking obesity and cancer risk: new perspectives. , 2010, Annual review of medicine.

[57]  Julie L Prior,et al.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. , 2009, Blood.

[58]  D. Rose,et al.  Angiogenesis, adipokines and breast cancer. , 2009, Cytokine & growth factor reviews.

[59]  Amy M. Fulton,et al.  The chemokine receptors CXCR4 and CXCR3 in cancer , 2009, Current oncology reports.

[60]  A. Ostman,et al.  Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. , 2009, Current opinion in genetics & development.

[61]  R. Horuk,et al.  Chemokine receptor antagonists: part 2 , 2009, Expert opinion on therapeutic patents.

[62]  R. Horuk,et al.  Chemokine receptor antagonists: Part 1 , 2009, Expert opinion on therapeutic patents.

[63]  J. Mesirov,et al.  Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. , 2008, Cancer research.

[64]  G. Giannelli,et al.  Blocking transforming growth factor–beta up‐regulates E‐cadherin and reduces migration and invasion of hepatocellular carcinoma cells , 2008, Hepatology.

[65]  W. Hung,et al.  Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. , 2008, Journal of clinical pathology.

[66]  M. Mack,et al.  Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. , 2007, The Journal of clinical investigation.

[67]  S. Sozzani,et al.  MCP‐3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells , 2007, International journal of cancer.

[68]  J. Isaacs,et al.  A Non-Glycosaminoglycan-Binding Variant of CC Chemokine Ligand 7 (Monocyte Chemoattractant Protein-3) Antagonizes Chemokine-Mediated Inflammation1 , 2005, The Journal of Immunology.

[69]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[70]  Brian Barnett,et al.  Bone Marrow Is a Reservoir for CD4+CD25+ Regulatory T Cells that Traffic through CXCL12/CXCR4 Signals , 2004, Cancer Research.

[71]  K. Vanderkerken,et al.  Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3 , 2003, British Journal of Cancer.

[72]  Guan-Cheng Li,et al.  Transfection of colorectal cancer cells with chemokine MCP-3 (monocyte chemotactic protein-3) gene retards tumor growth and inhibits tumor metastasis. , 2002, World journal of gastroenterology.

[73]  J. Van Damme,et al.  Macrophage inflammatory protein-1. , 2002, Cytokine & growth factor reviews.

[74]  J. Van Damme,et al.  Monocyte chemotactic protein-3. , 2002, European cytokine network.

[75]  N. Giese,et al.  Transduction of human MCP‐3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts , 2001, The journal of gene medicine.

[76]  M. Thelen,et al.  Dancing to the tune of chemokines , 2001, Nature Immunology.

[77]  R. Doms,et al.  CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. , 1999, Blood.

[78]  A. Mantovani,et al.  The chemokine system: redundancy for robust outputs. , 1999, Immunology today.

[79]  G. Opdenakker,et al.  Differential induction of monocyte chemotactic protein‐3 in mononuclear leukocytes and fibroblasts by interferon‐α / β and interferon‐γ reveals MCP‐3 heterogeneity , 1999 .

[80]  C. Garlanda,et al.  Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. , 1998, Journal of immunology.

[81]  M. Baggiolini.  Chemokines and leukocyte traffic , 1998, Nature.

[82]  E. Butcher,et al.  Chemokines and the arrest of lymphocytes rolling under flow conditions. , 1998, Science.

[83]  B Dewald,et al.  Human chemokines: an update. , 1997, Annual review of immunology.

[84]  Ji Ming Wang,et al.  Monocyte chemotactic protein‐3 (MCP3) interacts with multiple leukocyte receptors: binding and signaling of MCP3 through shared as well as unique receptors on monocytes and neutrophils , 1995, European journal of immunology.

[85]  P. Allavena,et al.  Induction of natural killer cell migration by monocyte chemotactic protein−1, −2 and −3 , 1994, European journal of immunology.

[86]  G. Opdenakker,et al.  Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family , 1992, The Journal of experimental medicine.